JP2020536915A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020536915A5 JP2020536915A5 JP2020520532A JP2020520532A JP2020536915A5 JP 2020536915 A5 JP2020536915 A5 JP 2020536915A5 JP 2020520532 A JP2020520532 A JP 2020520532A JP 2020520532 A JP2020520532 A JP 2020520532A JP 2020536915 A5 JP2020536915 A5 JP 2020536915A5
- Authority
- JP
- Japan
- Prior art keywords
- fluoro
- phenyl
- triazole
- dihydro
- pyrrolo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 C 1- C 6 alkyl Chemical group 0.000 claims 40
- 150000001875 compounds Chemical class 0.000 claims 21
- 150000003839 salts Chemical class 0.000 claims 20
- 125000004093 cyano group Chemical group *C#N 0.000 claims 18
- 125000001153 fluoro group Chemical group F* 0.000 claims 18
- 229910052739 hydrogen Inorganic materials 0.000 claims 17
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 15
- 239000001257 hydrogen Substances 0.000 claims 15
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 15
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 11
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 11
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 11
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 claims 9
- 229910052799 carbon Inorganic materials 0.000 claims 9
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 9
- 208000002320 spinal muscular atrophy Diseases 0.000 claims 9
- 125000001424 substituent group Chemical group 0.000 claims 9
- 125000000623 heterocyclic group Chemical group 0.000 claims 8
- 229910052736 halogen Inorganic materials 0.000 claims 7
- 150000002367 halogens Chemical class 0.000 claims 7
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 7
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims 6
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims 6
- 206010012289 Dementia Diseases 0.000 claims 6
- 206010033799 Paralysis Diseases 0.000 claims 6
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 6
- 125000004432 carbon atom Chemical group C* 0.000 claims 6
- 229910052757 nitrogen Inorganic materials 0.000 claims 6
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 6
- 208000021090 palsy Diseases 0.000 claims 6
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- NSPMIYGKQJPBQR-UHFFFAOYSA-N 4H-1,2,4-triazole Chemical compound C=1N=CNN=1 NSPMIYGKQJPBQR-UHFFFAOYSA-N 0.000 claims 4
- 125000003545 alkoxy group Chemical group 0.000 claims 4
- 125000000217 alkyl group Chemical group 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 125000004438 haloalkoxy group Chemical group 0.000 claims 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 4
- 125000004767 (C1-C4) haloalkoxy group Chemical group 0.000 claims 3
- 208000024827 Alzheimer disease Diseases 0.000 claims 3
- 206010008111 Cerebral haemorrhage Diseases 0.000 claims 3
- 208000032843 Hemorrhage Diseases 0.000 claims 3
- 208000023105 Huntington disease Diseases 0.000 claims 3
- 208000001089 Multiple system atrophy Diseases 0.000 claims 3
- 208000018737 Parkinson disease Diseases 0.000 claims 3
- 208000032319 Primary lateral sclerosis Diseases 0.000 claims 3
- 208000006011 Stroke Diseases 0.000 claims 3
- 208000034799 Tauopathies Diseases 0.000 claims 3
- 206010046298 Upper motor neurone lesion Diseases 0.000 claims 3
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 3
- 208000034158 bleeding Diseases 0.000 claims 3
- 230000000740 bleeding effect Effects 0.000 claims 3
- 125000001309 chloro group Chemical group Cl* 0.000 claims 3
- 229910052731 fluorine Inorganic materials 0.000 claims 3
- 125000001072 heteroaryl group Chemical group 0.000 claims 3
- 238000007917 intracranial administration Methods 0.000 claims 3
- 208000028867 ischemia Diseases 0.000 claims 3
- 201000010901 lateral sclerosis Diseases 0.000 claims 3
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 claims 3
- 208000005264 motor neuron disease Diseases 0.000 claims 3
- 201000000585 muscular atrophy Diseases 0.000 claims 3
- 201000006938 muscular dystrophy Diseases 0.000 claims 3
- 208000033808 peripheral neuropathy Diseases 0.000 claims 3
- 230000000750 progressive effect Effects 0.000 claims 3
- 201000008752 progressive muscular atrophy Diseases 0.000 claims 3
- 229910052717 sulfur Inorganic materials 0.000 claims 3
- 208000011580 syndromic disease Diseases 0.000 claims 3
- 230000002123 temporal effect Effects 0.000 claims 3
- KPKUNSHYTZNQGB-STQMWFEESA-N (5S,7S)-2-(2-ethoxyethyl)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole Chemical compound CCOCCC1=NN2[C@@H](C[C@H](F)C2=N1)C1=CC=CC=C1 KPKUNSHYTZNQGB-STQMWFEESA-N 0.000 claims 2
- IOASJLGDLUGRAU-KBPBESRZSA-N (5S,7S)-2-(cyclobutylmethyl)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole Chemical compound F[C@H]1C[C@H](N2N=C(CC3CCC3)N=C12)C1=CC=CC=C1 IOASJLGDLUGRAU-KBPBESRZSA-N 0.000 claims 2
- ALCTUKGOYARRNH-AVGNSLFASA-N (5S,7S)-2-[(S)-cyclopropyl(fluoro)methyl]-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole Chemical compound F[C@@H](C1CC1)C1=NN2[C@@H](C[C@H](F)C2=N1)C1=CC=CC=C1 ALCTUKGOYARRNH-AVGNSLFASA-N 0.000 claims 2
- UHAUTGSTWXFJTQ-YWGVVOLTSA-N (5S,7S)-2-[1-bicyclo[1.1.1]pentanyl(difluoro)methyl]-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole Chemical compound C1=CC=CC=C1[C@H]1N2C([C@H](C1)F)=NC(C(C13CC(C1)C3)(F)F)=N2 UHAUTGSTWXFJTQ-YWGVVOLTSA-N 0.000 claims 2
- JEGJYXYMPWLQOO-RYUDHWBXSA-N (5S,7S)-2-[cyclopropyl(difluoro)methyl]-7-fluoro-5-(2-fluorophenyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole Chemical compound F[C@H]1C[C@H](N2N=C(N=C12)C(F)(F)C1CC1)C1=C(F)C=CC=C1 JEGJYXYMPWLQOO-RYUDHWBXSA-N 0.000 claims 2
- MUJRUMLHIAZTAZ-BQUFFADESA-N (5S,7S)-7-fluoro-2-[(1S,2S)-2-methylcyclopropyl]-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole Chemical compound C[C@H]1C[C@@H]1C1=NN2[C@@H](C[C@H](F)C2=N1)C1=CC=CC=C1 MUJRUMLHIAZTAZ-BQUFFADESA-N 0.000 claims 2
- RXUYYIANSGIRBA-STQMWFEESA-N (5S,7S)-7-fluoro-5-phenyl-2-(propan-2-yloxymethyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole Chemical compound CC(C)OCC1=NN2[C@@H](C[C@H](F)C2=N1)C1=CC=CC=C1 RXUYYIANSGIRBA-STQMWFEESA-N 0.000 claims 2
- GDTCUGRIYFPSJN-UHFFFAOYSA-N 2-[(2,2-difluorocyclopropyl)methyl]-7-fluoro-5-(2-fluorophenyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole Chemical compound FC1CC(c2ccccc2F)n2nc(CC3CC3(F)F)nc12 GDTCUGRIYFPSJN-UHFFFAOYSA-N 0.000 claims 2
- 208000016192 Demyelinating disease Diseases 0.000 claims 2
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 claims 2
- 230000002490 cerebral effect Effects 0.000 claims 2
- 229910052801 chlorine Inorganic materials 0.000 claims 2
- 230000001054 cortical effect Effects 0.000 claims 2
- 230000007850 degeneration Effects 0.000 claims 2
- 125000004786 difluoromethoxy group Chemical group [H]C(F)(F)O* 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 125000005842 heteroatom Chemical group 0.000 claims 2
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims 2
- 229910052760 oxygen Inorganic materials 0.000 claims 2
- 239000001301 oxygen Chemical group 0.000 claims 2
- 201000002212 progressive supranuclear palsy Diseases 0.000 claims 2
- 125000004434 sulfur atom Chemical group 0.000 claims 2
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 2
- WDRYHJYWUJHCFD-RNJOBUHISA-N (1R,2R)-2-[(5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]cyclopropane-1-carbonitrile Chemical compound F[C@H]1C[C@@H](c2ccccc2)n2nc(nc12)[C@@H]1C[C@H]1C#N WDRYHJYWUJHCFD-RNJOBUHISA-N 0.000 claims 1
- FHXFRFFNQZTYIR-IALDZJHCSA-N (1S,2S)-2-[difluoro-(7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl)methyl]cyclopropane-1-carbonitrile Chemical compound FC([C@@H]1[C@H](C1)C#N)(C=1N=C2N(N=1)C(CC2F)C1=CC=CC=C1)F FHXFRFFNQZTYIR-IALDZJHCSA-N 0.000 claims 1
- BKAOETZHKDXDGK-RKDXNWHRSA-N (5R,7R)-2-(difluoromethyl)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole Chemical compound FC(F)C1=NN2[C@H](C[C@@H](F)C2=N1)C1=CC=CC=C1 BKAOETZHKDXDGK-RKDXNWHRSA-N 0.000 claims 1
- PMUFTGWGLJZNOX-ZDUSSCGKSA-N (5S)-2-(cyclopropylmethyl)-5-(2-fluorophenyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole Chemical compound FC1=C(C=CC=C1)[C@@H]1CCC2=NC(CC3CC3)=NN12 PMUFTGWGLJZNOX-ZDUSSCGKSA-N 0.000 claims 1
- JCPPXNOEDKUSMA-LBPRGKRZSA-N (5S)-5-(2-fluorophenyl)-2-propyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole Chemical compound CCCC1=NN2[C@@H](CCC2=N1)C1=C(F)C=CC=C1 JCPPXNOEDKUSMA-LBPRGKRZSA-N 0.000 claims 1
- VBFUHRXFACWWGQ-DVRYWGNFSA-N (5S,7S)-2-(2,2-difluorocyclopropyl)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole Chemical compound F[C@H]1C[C@H](N2N=C(N=C12)C1CC1(F)F)C1=CC=CC=C1 VBFUHRXFACWWGQ-DVRYWGNFSA-N 0.000 claims 1
- WLVQXZPCKIROOP-SPOOISQMSA-N (5S,7S)-2-(2,2-dimethylcyclopropyl)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole Chemical compound CC1(C)CC1C1=NN2[C@@H](C[C@H](F)C2=N1)C1=CC=CC=C1 WLVQXZPCKIROOP-SPOOISQMSA-N 0.000 claims 1
- LICTZQWETXXEHP-QWRGUYRKSA-N (5S,7S)-2-(2-chloroimidazol-1-yl)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole Chemical compound F[C@H]1C[C@H](N2N=C(N=C12)N1C=CN=C1Cl)C1=CC=CC=C1 LICTZQWETXXEHP-QWRGUYRKSA-N 0.000 claims 1
- CNUBVSIYBTVMDH-KBPBESRZSA-N (5S,7S)-2-(2-cyclopropylethynyl)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole Chemical compound F[C@H]1C[C@H](N2N=C(N=C12)C#CC1CC1)C1=CC=CC=C1 CNUBVSIYBTVMDH-KBPBESRZSA-N 0.000 claims 1
- NROHODVQFPILMY-QWRGUYRKSA-N (5S,7S)-2-(3,3-difluoropropyl)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole Chemical compound FC(F)CCC1=NN2[C@@H](C[C@H](F)C2=N1)C1=CC=CC=C1 NROHODVQFPILMY-QWRGUYRKSA-N 0.000 claims 1
- CYUQVAGRGYEPQD-KBPBESRZSA-N (5S,7S)-2-(4,5-dimethylimidazol-1-yl)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole Chemical compound CC1=C(C)N(C=N1)C1=NN2[C@@H](C[C@H](F)C2=N1)C1=CC=CC=C1 CYUQVAGRGYEPQD-KBPBESRZSA-N 0.000 claims 1
- MSAYVCFDYBZMAP-QWRGUYRKSA-N (5S,7S)-2-(4-chloroimidazol-1-yl)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole Chemical compound F[C@H]1C[C@H](N2N=C(N=C12)N1C=NC(Cl)=C1)C1=CC=CC=C1 MSAYVCFDYBZMAP-QWRGUYRKSA-N 0.000 claims 1
- QBKVTLIQUSUQRS-RYUDHWBXSA-N (5S,7S)-2-(4-chloropyrazol-1-yl)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole Chemical compound F[C@H]1C[C@H](N2N=C(N=C12)N1C=C(Cl)C=N1)C1=CC=CC=C1 QBKVTLIQUSUQRS-RYUDHWBXSA-N 0.000 claims 1
- FLYMGQORFVCALO-GJZGRUSLSA-N (5S,7S)-2-(4-cyclopropylpyrazol-1-yl)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole Chemical compound F[C@H]1C[C@H](N2N=C(N=C12)N1C=C(C=N1)C1CC1)C1=CC=CC=C1 FLYMGQORFVCALO-GJZGRUSLSA-N 0.000 claims 1
- FSNONCHUJMFFJY-KBPBESRZSA-N (5S,7S)-2-(4-ethylpyrazol-1-yl)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole Chemical compound CCC1=CN(N=C1)C1=NN2[C@@H](C[C@H](F)C2=N1)C1=CC=CC=C1 FSNONCHUJMFFJY-KBPBESRZSA-N 0.000 claims 1
- YASNUJHAYIJJNC-RAMGSTBQSA-N (5S,7S)-2-[(2,2-difluorocyclopropyl)methyl]-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole Chemical compound F[C@H]1C[C@H](N2N=C(CC3CC3(F)F)N=C12)C1=CC=CC=C1 YASNUJHAYIJJNC-RAMGSTBQSA-N 0.000 claims 1
- HZAROVNAMRBNGP-CLJTZFLHSA-N (5S,7S)-2-[(R)-1-bicyclo[1.1.1]pentanyl(fluoro)methyl]-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole Chemical compound C1=CC=CC=C1[C@H]1N2C([C@H](C1)F)=NC([C@@H](C13CC(C1)C3)F)=N2 HZAROVNAMRBNGP-CLJTZFLHSA-N 0.000 claims 1
- ALCTUKGOYARRNH-RWMBFGLXSA-N (5S,7S)-2-[(R)-cyclopropyl(fluoro)methyl]-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole Chemical compound F[C@H](C1CC1)C1=NN2[C@@H](C[C@H](F)C2=N1)C1=CC=CC=C1 ALCTUKGOYARRNH-RWMBFGLXSA-N 0.000 claims 1
- HZAROVNAMRBNGP-UGLBVFMYSA-N (5S,7S)-2-[(S)-1-bicyclo[1.1.1]pentanyl(fluoro)methyl]-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole Chemical compound C1=CC=CC=C1[C@H]1N2C([C@@H](F)C1)=NC(=N2)[C@H](C12CC(C1)C2)F HZAROVNAMRBNGP-UGLBVFMYSA-N 0.000 claims 1
- GVXHTMMRYFHKSQ-RYUDHWBXSA-N (5S,7S)-2-[cyclopropyl(difluoro)methyl]-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole Chemical compound F[C@H]1C[C@H](N2N=C(N=C12)C(F)(F)C1CC1)C1=CC=CC=C1 GVXHTMMRYFHKSQ-RYUDHWBXSA-N 0.000 claims 1
- LTFXUKMFJNTABL-STQMWFEESA-N (5S,7S)-2-but-1-en-2-yl-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole Chemical compound CCC(=C)C1=NN2[C@@H](C[C@H](F)C2=N1)C1=CC=CC=C1 LTFXUKMFJNTABL-STQMWFEESA-N 0.000 claims 1
- NUZSTKOHEMQTRQ-QWRGUYRKSA-N (5S,7S)-2-ethenyl-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole Chemical compound F[C@H]1C[C@H](N2N=C(C=C)N=C12)C1=CC=CC=C1 NUZSTKOHEMQTRQ-QWRGUYRKSA-N 0.000 claims 1
- KGPQVYVRXMOVKQ-RYUDHWBXSA-N (5S,7S)-7-fluoro-2-(1-methylimidazol-2-yl)-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole Chemical compound CN1C=CN=C1C1=NN2[C@@H](C[C@H](F)C2=N1)C1=CC=CC=C1 KGPQVYVRXMOVKQ-RYUDHWBXSA-N 0.000 claims 1
- NULLQENWXKEGAA-STQMWFEESA-N (5S,7S)-7-fluoro-2-(2-methylimidazol-1-yl)-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole Chemical compound CC1=NC=CN1C1=NN2[C@@H](C[C@H](F)C2=N1)C1=CC=CC=C1 NULLQENWXKEGAA-STQMWFEESA-N 0.000 claims 1
- ZJSLXLZEVNZLOX-QWRGUYRKSA-N (5S,7S)-7-fluoro-2-(4-fluoroimidazol-1-yl)-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole Chemical compound F[C@H]1C[C@H](N2N=C(N=C12)N1C=NC(F)=C1)C1=CC=CC=C1 ZJSLXLZEVNZLOX-QWRGUYRKSA-N 0.000 claims 1
- PLSQSURQPYGYGM-RYUDHWBXSA-N (5S,7S)-7-fluoro-2-(4-fluoropyrazol-1-yl)-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole Chemical compound F[C@H]1C[C@H](N2N=C(N=C12)N1C=C(F)C=N1)C1=CC=CC=C1 PLSQSURQPYGYGM-RYUDHWBXSA-N 0.000 claims 1
- WCMWOUHEAUMMDL-STQMWFEESA-N (5S,7S)-7-fluoro-2-(4-methoxypyrazol-1-yl)-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole Chemical compound COC1=CN(N=C1)C1=NN2[C@@H](C[C@H](F)C2=N1)C1=CC=CC=C1 WCMWOUHEAUMMDL-STQMWFEESA-N 0.000 claims 1
- RKMIQCIBZJBJTH-STQMWFEESA-N (5S,7S)-7-fluoro-2-(4-methylsulfonylpyrazol-1-yl)-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole Chemical compound CS(=O)(=O)C1=CN(N=C1)C1=NN2[C@@H](C[C@H](F)C2=N1)C1=CC=CC=C1 RKMIQCIBZJBJTH-STQMWFEESA-N 0.000 claims 1
- MIRIPTKIMZOSGE-RYUDHWBXSA-N (5S,7S)-7-fluoro-2-(5-methyl-1,2,4-triazol-1-yl)-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole Chemical compound CC1=NC=NN1C1=NN2[C@@H](C[C@H](F)C2=N1)C1=CC=CC=C1 MIRIPTKIMZOSGE-RYUDHWBXSA-N 0.000 claims 1
- RGTCHMJHRGZKQJ-STQMWFEESA-N (5S,7S)-7-fluoro-2-(5-methylpyrazol-1-yl)-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole Chemical compound CC1=CC=NN1C1=NN2[C@@H](C[C@H](F)C2=N1)C1=CC=CC=C1 RGTCHMJHRGZKQJ-STQMWFEESA-N 0.000 claims 1
- UMJVNPXGZIEYDO-RYUDHWBXSA-N (5S,7S)-7-fluoro-2-imidazol-1-yl-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole Chemical compound F[C@H]1C[C@H](N2N=C(N=C12)N1C=CN=C1)C1=CC=CC=C1 UMJVNPXGZIEYDO-RYUDHWBXSA-N 0.000 claims 1
- GGRANSKWVSEKOT-QWRGUYRKSA-N (5S,7S)-7-fluoro-5-phenyl-2-(1,2,4-triazol-1-yl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole Chemical compound F[C@H]1C[C@H](N2N=C(N=C12)N1C=NC=N1)C1=CC=CC=C1 GGRANSKWVSEKOT-QWRGUYRKSA-N 0.000 claims 1
- UNGACTKJXUJRLY-QWRGUYRKSA-N (5S,7S)-7-fluoro-5-phenyl-2-(3,3,3-trifluoropropyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole Chemical compound F[C@H]1C[C@H](N2N=C(CCC(F)(F)F)N=C12)C1=CC=CC=C1 UNGACTKJXUJRLY-QWRGUYRKSA-N 0.000 claims 1
- PCHGYNYQBVSCGW-GJZGRUSLSA-N (5S,7S)-7-fluoro-5-phenyl-2-(4-propan-2-ylpyrazol-1-yl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole Chemical compound CC(C)C1=CN(N=C1)C1=NN2[C@@H](C[C@H](F)C2=N1)C1=CC=CC=C1 PCHGYNYQBVSCGW-GJZGRUSLSA-N 0.000 claims 1
- FBFFUBGPDIFCII-HOCLYGCPSA-N (5S,7S)-7-fluoro-5-phenyl-2-(4-pyrimidin-4-ylpyrazol-1-yl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole Chemical compound F[C@H]1C[C@H](N2N=C(N=C12)N1C=C(C=N1)C1=CC=NC=N1)C1=CC=CC=C1 FBFFUBGPDIFCII-HOCLYGCPSA-N 0.000 claims 1
- JRSRNWRPWAZQSM-QWRGUYRKSA-N (5S,7S)-7-fluoro-5-phenyl-2-[3-(trifluoromethyl)pyrazol-1-yl]-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole Chemical compound F[C@H]1C[C@H](N2N=C(N=C12)N1C=CC(=N1)C(F)(F)F)C1=CC=CC=C1 JRSRNWRPWAZQSM-QWRGUYRKSA-N 0.000 claims 1
- RKCNZELLMJOPCJ-QWRGUYRKSA-N (5S,7S)-7-fluoro-5-phenyl-2-[4-(trifluoromethyl)imidazol-1-yl]-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole Chemical compound F[C@H]1C[C@H](N2N=C(N=C12)N1C=NC(=C1)C(F)(F)F)C1=CC=CC=C1 RKCNZELLMJOPCJ-QWRGUYRKSA-N 0.000 claims 1
- QTFYEBZUVXSPQI-RYUDHWBXSA-N (5S,7S)-7-fluoro-5-phenyl-2-[4-(trifluoromethyl)pyrazol-1-yl]-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole Chemical compound F[C@H]1C[C@H](N2N=C(N=C12)N1C=C(C=N1)C(F)(F)F)C1=CC=CC=C1 QTFYEBZUVXSPQI-RYUDHWBXSA-N 0.000 claims 1
- LCZXCYYKYOZYHG-RYUDHWBXSA-N (5S,7S)-7-fluoro-5-phenyl-2-propyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole Chemical compound CCCC1=NN2[C@@H](C[C@H](F)C2=N1)C1=CC=CC=C1 LCZXCYYKYOZYHG-RYUDHWBXSA-N 0.000 claims 1
- ADFFEHJDGDXCFG-UWVGGRQHSA-N (5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole Chemical compound F[C@H]1C[C@H](N2N=CN=C21)C2=CC=CC=C2 ADFFEHJDGDXCFG-UWVGGRQHSA-N 0.000 claims 1
- 125000006677 (C1-C3) haloalkoxy group Chemical group 0.000 claims 1
- 125000006699 (C1-C3) hydroxyalkyl group Chemical group 0.000 claims 1
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 claims 1
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 claims 1
- 125000006661 (C4-C6) heterocyclic group Chemical group 0.000 claims 1
- UGOJIEZBRQLYGD-AVGNSLFASA-N (R)-[(5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]-(1-methylcyclopropyl)methanol Chemical compound CC1(CC1)[C@@H](O)C1=NN2[C@@H](C[C@H](F)C2=N1)C1=CC=CC=C1 UGOJIEZBRQLYGD-AVGNSLFASA-N 0.000 claims 1
- OPEZCPOFJGMWSL-XNRPHZJLSA-N (R)-cyclopropyl-[(4R,6R)-4-fluoro-6-phenyl-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-2-yl]methanol Chemical compound O[C@H](C1CC1)C1=NN2[C@H](C[C@@H](F)C2=C1)C1=CC=CC=C1 OPEZCPOFJGMWSL-XNRPHZJLSA-N 0.000 claims 1
- OPEZCPOFJGMWSL-XPKDYRNWSA-N (S)-cyclopropyl-[(4R,6R)-4-fluoro-6-phenyl-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-2-yl]methanol Chemical compound O[C@@H](C1CC1)C1=NN2[C@H](C[C@@H](F)C2=C1)C1=CC=CC=C1 OPEZCPOFJGMWSL-XPKDYRNWSA-N 0.000 claims 1
- DMAYXWLZZCHGOM-AVGNSLFASA-N (S)-cyclopropyl-[(5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]methanol Chemical compound O[C@@H](C1CC1)C1=NN2[C@@H](C[C@H](F)C2=N1)C1=CC=CC=C1 DMAYXWLZZCHGOM-AVGNSLFASA-N 0.000 claims 1
- YLWFWAJVUXDHBN-RYUDHWBXSA-N 1-[(5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]-3-methylimidazol-2-one Chemical compound CN1C=CN(C1=O)C1=NN2[C@@H](C[C@H](F)C2=N1)C1=CC=CC=C1 YLWFWAJVUXDHBN-RYUDHWBXSA-N 0.000 claims 1
- YRUHLRURKWSWSY-WFASDCNBSA-N 1-[(5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]-4,5,6,7-tetrahydrobenzotriazole Chemical compound F[C@H]1C[C@H](N2N=C(N=C12)N1N=NC2=C1CCCC2)C1=CC=CC=C1 YRUHLRURKWSWSY-WFASDCNBSA-N 0.000 claims 1
- HJPCDANETGJRIT-BBRMVZONSA-N 1-[(5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]-5-methylbenzotriazole Chemical compound CC1=CC=C2N(N=NC2=C1)C1=NN2[C@@H](C[C@H](F)C2=N1)C1=CC=CC=C1 HJPCDANETGJRIT-BBRMVZONSA-N 0.000 claims 1
- SZRAAOPNACZGLP-STQMWFEESA-N 1-[(5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]azetidine-3-carbonitrile Chemical compound F[C@H]1C[C@H](N2N=C(N=C12)N1CC(C1)C#N)C1=CC=CC=C1 SZRAAOPNACZGLP-STQMWFEESA-N 0.000 claims 1
- UVXLRCCDEWWKBT-WFASDCNBSA-N 1-[(5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]benzotriazole Chemical compound F[C@H]1C[C@H](N2N=C(N=C12)N1N=NC2=CC=CC=C12)C1=CC=CC=C1 UVXLRCCDEWWKBT-WFASDCNBSA-N 0.000 claims 1
- SQKQCCLSQQAYBZ-BBRMVZONSA-N 1-[(5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]benzotriazole-5-carbonitrile Chemical compound F[C@H]1C[C@H](N2N=C(N=C12)N1N=NC2=CC(=CC=C12)C#N)C1=CC=CC=C1 SQKQCCLSQQAYBZ-BBRMVZONSA-N 0.000 claims 1
- KOMHOOPRVFWEOZ-HOCLYGCPSA-N 1-[(5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]indazole Chemical compound F[C@H]1C[C@H](N2N=C(N=C12)N1N=CC2=CC=CC=C12)C1=CC=CC=C1 KOMHOOPRVFWEOZ-HOCLYGCPSA-N 0.000 claims 1
- UFFROGBGVWPLFC-RDJZCZTQSA-N 1-[(5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]indazole-4-carbonitrile Chemical compound F[C@H]1C[C@H](N2N=C(N=C12)N1N=CC2=C(C=CC=C12)C#N)C1=CC=CC=C1 UFFROGBGVWPLFC-RDJZCZTQSA-N 0.000 claims 1
- PYQICFMOUMYUKJ-KBPBESRZSA-N 1-[(5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]pyrazolo[3,4-c]pyridine Chemical compound F[C@H]1C[C@H](N2N=C(N=C12)N1N=CC2=CC=NC=C12)C1=CC=CC=C1 PYQICFMOUMYUKJ-KBPBESRZSA-N 0.000 claims 1
- WKJNBSYNPDWHNO-WFASDCNBSA-N 1-[(5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]pyrazolo[4,3-b]pyridine Chemical compound F[C@H]1C[C@H](N2N=C(N=C12)N1N=CC2=NC=CC=C12)C1=CC=CC=C1 WKJNBSYNPDWHNO-WFASDCNBSA-N 0.000 claims 1
- IJHFYYQPHHHCSX-ZFWWWQNUSA-N 1-[(5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]pyrazolo[4,3-c]pyridine Chemical compound F[C@H]1C[C@H](N2N=C(N=C12)N1N=CC2=CN=CC=C12)C1=CC=CC=C1 IJHFYYQPHHHCSX-ZFWWWQNUSA-N 0.000 claims 1
- BQNBBNDHIKLFIF-FZMZJTMJSA-N 1-[(5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]triazolo[4,5-c]pyridine Chemical compound F[C@H]1C[C@H](N2N=C(N=C12)N1N=NC2=CN=CC=C12)C1=CC=CC=C1 BQNBBNDHIKLFIF-FZMZJTMJSA-N 0.000 claims 1
- UMEIRKLCOZBPHW-STQMWFEESA-N 1-[[(5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]methyl]cyclopropane-1-carbonitrile Chemical compound F[C@H]1C[C@H](N2N=C(CC3(CC3)C#N)N=C12)C1=CC=CC=C1 UMEIRKLCOZBPHW-STQMWFEESA-N 0.000 claims 1
- LRGBDJBDJXZTTD-UHFFFAOYSA-N 1h-pyrazole-4-carbaldehyde Chemical compound O=CC=1C=NNC=1 LRGBDJBDJXZTTD-UHFFFAOYSA-N 0.000 claims 1
- NUGZBVBZIDWZAD-UHFFFAOYSA-N 1h-pyrazole-4-carbonitrile Chemical compound N#CC=1C=NNC=1 NUGZBVBZIDWZAD-UHFFFAOYSA-N 0.000 claims 1
- YMJLEPMVGQBLHL-UHFFFAOYSA-N 1h-pyrazole-5-carbonitrile Chemical compound N#CC1=CC=NN1 YMJLEPMVGQBLHL-UHFFFAOYSA-N 0.000 claims 1
- SAQMQGKIKVSNOD-UHFFFAOYSA-N 2-(7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl)acetonitrile Chemical compound FC1CC(c2ccccc2)n2nc(CC#N)nc12 SAQMQGKIKVSNOD-UHFFFAOYSA-N 0.000 claims 1
- AXQIAEBXRKJZJE-UHFFFAOYSA-N 2-[(7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl)methoxy]acetonitrile Chemical compound FC1CC(N2N=C(COCC#N)N=C12)C1=CC=CC=C1 AXQIAEBXRKJZJE-UHFFFAOYSA-N 0.000 claims 1
- MESPBSCMVDRXIP-RYUDHWBXSA-N 3-[(5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]propanenitrile Chemical compound F[C@H]1C[C@H](N2N=C(CCC#N)N=C12)C1=CC=CC=C1 MESPBSCMVDRXIP-RYUDHWBXSA-N 0.000 claims 1
- UPRSJJWIJUQFBW-AAEUAGOBSA-N 3-[(5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]triazolo[4,5-c]pyridine Chemical compound F[C@H]1C[C@H](N2N=C(N=C12)N1N=NC2=CC=NC=C12)C1=CC=CC=C1 UPRSJJWIJUQFBW-AAEUAGOBSA-N 0.000 claims 1
- LXSMMVPWDUDHMH-ZRNAQANOSA-N 3-[[(5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]methylidene]cyclobutane-1-carbonitrile Chemical compound F[C@H]1C[C@H](N2N=C(C=C3CC(C3)C#N)N=C12)C1=CC=CC=C1 LXSMMVPWDUDHMH-ZRNAQANOSA-N 0.000 claims 1
- WUEGVYLRQGZTAH-RYUDHWBXSA-N 4-[(5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]-1,2-oxazole Chemical compound F[C@H]1C[C@H](N2N=C(N=C12)C1=CON=C1)C1=CC=CC=C1 WUEGVYLRQGZTAH-RYUDHWBXSA-N 0.000 claims 1
- 125000001054 5 membered carbocyclic group Chemical group 0.000 claims 1
- 125000003627 8 membered carbocyclic group Chemical group 0.000 claims 1
- 125000005330 8 membered heterocyclic group Chemical group 0.000 claims 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 claims 1
- UNGACTKJXUJRLY-GHMZBOCLSA-N F[C@@H]1C[C@@H](N2N=C(CCC(F)(F)F)N=C12)C1=CC=CC=C1 Chemical compound F[C@@H]1C[C@@H](N2N=C(CCC(F)(F)F)N=C12)C1=CC=CC=C1 UNGACTKJXUJRLY-GHMZBOCLSA-N 0.000 claims 1
- 101001109145 Homo sapiens Receptor-interacting serine/threonine-protein kinase 1 Proteins 0.000 claims 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 1
- QRUDEWIWKLJBPS-UHFFFAOYSA-N benzotriazole Chemical compound C1=CC=C2N[N][N]C2=C1 QRUDEWIWKLJBPS-UHFFFAOYSA-N 0.000 claims 1
- 239000012964 benzotriazole Substances 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- YMGUBTXCNDTFJI-UHFFFAOYSA-M cyclopropanecarboxylate Chemical compound [O-]C(=O)C1CC1 YMGUBTXCNDTFJI-UHFFFAOYSA-M 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 1
- 125000004430 oxygen atom Chemical group O* 0.000 claims 1
- FVSKHRXBFJPNKK-UHFFFAOYSA-N propionitrile Chemical compound CCC#N FVSKHRXBFJPNKK-UHFFFAOYSA-N 0.000 claims 1
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims 1
- 239000011593 sulfur Chemical group 0.000 claims 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 claims 1
- 229920002554 vinyl polymer Polymers 0.000 claims 1
- 0 C*(C)(*)c1n[n](C(*)CC*)c(C*)n1 Chemical compound C*(C)(*)c1n[n](C(*)CC*)c(C*)n1 0.000 description 1
- PDDFUFAYZAFHRE-UHFFFAOYSA-N Cc1n[n](C(CC2F)c3cnccc3)c2n1 Chemical compound Cc1n[n](C(CC2F)c3cnccc3)c2n1 PDDFUFAYZAFHRE-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762570892P | 2017-10-11 | 2017-10-11 | |
| US62/570,892 | 2017-10-11 | ||
| PCT/EP2018/077656 WO2019072942A1 (en) | 2017-10-11 | 2018-10-10 | BICYCLIC COMPOUNDS FOR USE AS INHIBITORS OF KINASE RIP1 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020536915A JP2020536915A (ja) | 2020-12-17 |
| JP2020536915A5 true JP2020536915A5 (enExample) | 2021-11-25 |
| JP7362600B2 JP7362600B2 (ja) | 2023-10-17 |
Family
ID=63840848
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020520532A Active JP7362600B2 (ja) | 2017-10-11 | 2018-10-10 | Ｒｉｐ１キナーゼ阻害剤として使用するための二環式化合物 |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US11673892B2 (enExample) |
| EP (1) | EP3694858B1 (enExample) |
| JP (1) | JP7362600B2 (enExample) |
| KR (1) | KR20200070297A (enExample) |
| CN (1) | CN111201229B (enExample) |
| AU (1) | AU2018348930A1 (enExample) |
| BR (1) | BR112020007067A2 (enExample) |
| CA (1) | CA3078653A1 (enExample) |
| CL (1) | CL2020000944A1 (enExample) |
| CO (1) | CO2020004977A2 (enExample) |
| CR (1) | CR20200151A (enExample) |
| IL (1) | IL273443A (enExample) |
| MA (1) | MA50356A (enExample) |
| MX (1) | MX2020003439A (enExample) |
| PE (1) | PE20211246A1 (enExample) |
| PH (1) | PH12020550253A1 (enExample) |
| RU (1) | RU2020114670A (enExample) |
| SG (1) | SG11202003283TA (enExample) |
| WO (1) | WO2019072942A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11071721B2 (en) | 2016-12-02 | 2021-07-27 | Genentech, Inc. | Bicyclic amide compounds and methods of use thereof |
| CN119613408A (zh) * | 2017-07-14 | 2025-03-14 | 豪夫迈·罗氏有限公司 | 二环酮化合物及其使用方法 |
| MX2020003451A (es) | 2017-10-31 | 2020-08-03 | Hoffmann La Roche | Sulfonas y sulfoxidos biciclicos y metodos de uso de los mismos. |
| CN113302193B (zh) * | 2019-01-11 | 2026-05-29 | 豪夫迈·罗氏有限公司 | 双环吡咯并三唑酮化合物及其使用方法 |
| CN114591333B (zh) * | 2020-12-04 | 2023-08-01 | 广州嘉越医药科技有限公司 | 一种吡咯并嘧啶类化合物的制备方法 |
| CA3214802A1 (en) * | 2021-04-02 | 2022-10-06 | Genentech, Inc. | Processes for making bicyclic ketone compounds |
| WO2023039795A1 (zh) * | 2021-09-16 | 2023-03-23 | 维泰瑞隆（北京）生物科技有限公司 | Rip1激酶抑制剂及其用途 |
| WO2025261418A1 (zh) * | 2024-06-19 | 2025-12-26 | 成都赜灵生物医药科技有限公司 | 并芳基类化合物及其用途 |
| WO2026001865A1 (en) * | 2024-06-24 | 2026-01-02 | Sironax Ltd. | Rip1 modulators, preparations, and uses thereof |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| EP0102324A3 (de) | 1982-07-29 | 1984-11-07 | Ciba-Geigy Ag | Lipide und Tenside in wässriger Phase |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| HUT35524A (en) | 1983-08-02 | 1985-07-29 | Hoechst Ag | Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance |
| US5004697A (en) | 1987-08-17 | 1991-04-02 | Univ. Of Ca | Cationized antibodies for delivery through the blood-brain barrier |
| US5112596A (en) | 1990-04-23 | 1992-05-12 | Alkermes, Inc. | Method for increasing blood-brain barrier permeability by administering a bradykinin agonist of blood-brain barrier permeability |
| US5268164A (en) | 1990-04-23 | 1993-12-07 | Alkermes, Inc. | Increasing blood-brain barrier permeability with permeabilizer peptides |
| WO1992004343A1 (fr) * | 1990-09-04 | 1992-03-19 | Yamanouchi Pharmaceutical Co., Ltd. | Nouveau derive de tetrahydrobenzazole |
| AU677216B2 (en) | 1992-07-27 | 1997-04-17 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Targeting of liposomes to the blood-brain barrier |
| US6080772A (en) | 1995-06-07 | 2000-06-27 | Sugen, Inc. | Thiazole compounds and methods of modulating signal transduction |
| EP1007042A4 (en) | 1997-06-13 | 2001-07-04 | Sugen Inc | NEW HETEROCYCLIC COMPOUNDS FOR MODULATING THE PROTEIN-TYROSIN-ENZYME-RELATED CELLULAR SIGNAL TRANSDUCTION |
| US6514221B2 (en) | 2000-07-27 | 2003-02-04 | Brigham And Women's Hospital, Inc. | Blood-brain barrier opening |
| CA2416527C (en) | 2000-08-10 | 2009-12-22 | Pharmacia Italia S.P.A. | Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them |
| AU2001286930A1 (en) | 2000-08-30 | 2002-03-13 | The Board Of Trustees Of The Leland Stanford Junior University | Glucocorticoid blocking agents for increasing blood-brain barrier permeability |
| US7034036B2 (en) | 2000-10-30 | 2006-04-25 | Pain Therapeutics, Inc. | Inhibitors of ABC drug transporters at the blood-brain barrier |
| DE10121982B4 (de) | 2001-05-05 | 2008-01-24 | Lts Lohmann Therapie-Systeme Ag | Nanopartikel aus Protein mit gekoppeltem Apolipoprotein E zur Überwindung der Blut-Hirn-Schranke und Verfahren zu ihrer Herstellung |
| SI1397364T1 (sl) | 2001-05-24 | 2007-12-31 | Lilly Co Eli | Novi pirolni derivati kot farmacevtske uäśinkovine |
| CA2450073C (en) | 2001-07-25 | 2017-08-29 | Biomarin Pharmaceutical Inc. | Compositions and methods for modulating blood-brain barrier transport |
| US20030162695A1 (en) | 2002-02-27 | 2003-08-28 | Schatzberg Alan F. | Glucocorticoid blocking agents for increasing blood-brain barrier permeability |
| JP4995423B2 (ja) | 2002-12-03 | 2012-08-08 | ブランシェット・ロックフェラー・ニューロサイエンスィズ・インスティテュート | 物質を血液−脳関門を渡って輸送するための人工低密度リポタンパク質キャリア |
| WO2005025511A2 (en) | 2003-09-10 | 2005-03-24 | Cedars-Sinai Medical Center | Potassium channel mediated delivery of agents through the blood-brain barrier |
| EA017937B1 (ru) | 2007-02-07 | 2013-04-30 | Пфайзер Инк. | ПРОИЗВОДНЫЕ 3-АМИНОПИРРОЛО[3,4-c]ПИРАЗОЛ-5(1H,4H,6H)-КАРБАЛЬДЕГИДА В КАЧЕСТВЕ ИНГИБИТОРОВ РКС |
| JP2012051806A (ja) * | 2009-02-26 | 2012-03-15 | Eisai R & D Management Co Ltd | イミダゾリルピラジン誘導体 |
| WO2011006903A1 (en) | 2009-07-15 | 2011-01-20 | Ortho-Mcneil-Janssen Pharmaceuticals, Inc | Substituted triazole and imidazole derivatives as gamma secretase modulators |
| CN103874702B (zh) * | 2011-07-15 | 2015-12-09 | 杨森制药公司 | 作为γ分泌酶调节剂的经取代的吲哚衍生物 |
| JP6267193B2 (ja) | 2012-05-22 | 2018-01-24 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 置換ジピリジルアミン類及びそれらの使用 |
| MX2015009270A (es) | 2013-01-18 | 2015-10-30 | Hoffmann La Roche | Pirazoles sustituidos en posicion 3 y uso de los mismos como inhibidores de la cinasa cremallera de leucinas dual (dlk). |
| TWI648274B (zh) | 2013-02-15 | 2019-01-21 | 英商葛蘭素史克智慧財產發展有限公司 | 作為激酶抑制劑之雜環醯胺類 （二） |
| RU2015147601A (ru) | 2013-05-01 | 2017-06-05 | Ф. Хоффманн-Ля Рош Аг | С-связанные гетероциклоалкилзамещенные пиримидины и их применения |
| TWI710558B (zh) | 2013-05-01 | 2020-11-21 | 瑞士商赫孚孟拉羅股份公司 | 二雜芳基化合物及其用途 |
| MX2016008110A (es) | 2013-12-20 | 2016-08-19 | Hoffmann La Roche | Derivados de pirazol como inhibidores de la cinasa de cremallera de leucina dual (dlk) y usos de los mismos. |
| RU2017109122A (ru) | 2014-08-21 | 2018-09-21 | Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед | Способы лечения с использованием гетероциклических амидов в качестве ингибиторов киназы |
| JP6701225B2 (ja) | 2015-03-09 | 2020-05-27 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 三環式ｄｌｋ阻害剤及びその使用 |
| RU2716136C2 (ru) | 2015-07-02 | 2020-03-06 | Ф. Хоффманн-Ля Рош Аг | Бициклические лактамы и способы их применения |
| US9815850B2 (en) * | 2016-02-05 | 2017-11-14 | Denali Therapeutics Inc. | Compounds, compositions and methods |
| KR102613433B1 (ko) | 2017-10-11 | 2023-12-13 | 주식회사 대웅제약 | 신규한 페닐피리딘 유도체 및 이를 포함하는 약학 조성물 |
-
2018
- 2018-10-10 WO PCT/EP2018/077656 patent/WO2019072942A1/en not_active Ceased
- 2018-10-10 AU AU2018348930A patent/AU2018348930A1/en not_active Abandoned
- 2018-10-10 JP JP2020520532A patent/JP7362600B2/ja active Active
- 2018-10-10 CA CA3078653A patent/CA3078653A1/en active Pending
- 2018-10-10 EP EP18785936.8A patent/EP3694858B1/en active Active
- 2018-10-10 PE PE2020000378A patent/PE20211246A1/es unknown
- 2018-10-10 KR KR1020207013188A patent/KR20200070297A/ko not_active Ceased
- 2018-10-10 MA MA050356A patent/MA50356A/fr unknown
- 2018-10-10 CR CR20200151A patent/CR20200151A/es unknown
- 2018-10-10 RU RU2020114670A patent/RU2020114670A/ru unknown
- 2018-10-10 MX MX2020003439A patent/MX2020003439A/es unknown
- 2018-10-10 BR BR112020007067-0A patent/BR112020007067A2/pt not_active Application Discontinuation
- 2018-10-10 CN CN201880066460.0A patent/CN111201229B/zh active Active
- 2018-10-10 SG SG11202003283TA patent/SG11202003283TA/en unknown
-
2020
- 2020-03-19 IL IL273443A patent/IL273443A/en unknown
- 2020-04-08 CL CL2020000944A patent/CL2020000944A1/es unknown
- 2020-04-09 PH PH12020550253A patent/PH12020550253A1/en unknown
- 2020-04-09 US US16/844,952 patent/US11673892B2/en active Active
- 2020-04-23 CO CONC2020/0004977A patent/CO2020004977A2/es unknown